Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rauch

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Journal of Extracellular Vesicles|October 10, 2024
HTLV-1 infected T cells cause bone loss via small extracellular vesiclesNitin Kumar Pokhrel, Amanda R Panfil, Haniya Habib, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
HTLV-1 infected T cells cause bone loss via small extracellular vesiclesNitin Kumar Pokhrel, Amanda Panfil, Haniya Habib, et al.
Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.
BMC Cancer|October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Martin Bigler, Roger von Moos, et al.
Hospital Pediatrics|July 12, 2017
Current Scope of Practice for Newborn Care in Non-Intensive Hospital SettingsEsther K Chung, E Kaye Gable, W Christopher Golden, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Sarah Danson, Dunson Ejedepang, et al.
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of Extracellular Vesicles|October 10, 2024
HTLV-1 infected T cells cause bone loss via small extracellular vesiclesNitin Kumar Pokhrel, Amanda R Panfil, Haniya Habib, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
HTLV-1 infected T cells cause bone loss via small extracellular vesiclesNitin Kumar Pokhrel, Amanda Panfil, Haniya Habib, et al.
Blood Advances|December 4, 2020
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A Moccia, Christian Taverna, Sämi Schär, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Giovanni Martinelli, Felicitas Hitz, et al.
BMC Cancer|October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Martin Bigler, Roger von Moos, et al.
Hospital Pediatrics|July 12, 2017
Current Scope of Practice for Newborn Care in Non-Intensive Hospital SettingsEsther K Chung, E Kaye Gable, W Christopher Golden, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Sarah Danson, Dunson Ejedepang, et al.
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Pageof 6